From October 29 to 31, 2026, the 2026 China-Global Healthcare Investment and Partnership Summit (2026 CHIPS) was held in Hengqin, China. The summit brought together nearly a thousand participants from both China and abroad, spanning a diverse ecosystem of healthcare companies, research and clinical institutions, investors, and professional services, and covering major overseas markets across Europe, the Americas, the Middle East, and Latin America — successfully building a bridge that connects multiple industries, fields, and regions. Cao Jinfeng, Deputy Director of the Executive Committee of the Guangdong-Macao In-Depth Cooperation Zone in Hengqin and Chairman of the Council of the China-Portugal Economic and Trade Center, delivered a speech at the summit. He expressed the expectation of leveraging the opening advantages of Macao's free port to continue advancing policy alignment, industrial synergy, and institutional connectivity, with the goal of building a livable sci-tech "Peach Blossom Spring" for research, production, and trade. Aaron Gu, Partner at Han Kun Law Offices, was invited to the summit and joined the panel discussion on "Building World-Class BD Capabilities: The Competitiveness of Chinese Innovation in Globalization", sharing cutting-edge experience from the industry.
The 10th sub-forum, the "BD Excellence Advancement" session, was chaired by Dr. Jun Bao, Founder and Managing Partner of Apuri BioVenture, who designed and moderated the entire agenda. This panel discussion was one of the key agenda items of the session. Aaron Gu and the attending experts exchanged views in depth on topics such as how Chinese innovative drug and medical device companies can build systematic BD capabilities and strengthen their global competitiveness in international cooperation. Drawing on his extensive practical experience in biopharmaceutical cross border licensing transactions, Aaron Gu shared the key issues to watch and practical recommendations in cross border BD cooperation from a legal perspective, including transaction structure design and intellectual property arrangements, and offered insights into the latest regulatory developments in China's biopharmaceutical industry. The panel discussion provided useful references for Chinese innovative drug and medical device companies to improve their BD systems and steadily advance their globalization, and brought new thinking on how the industry can enhance the quality of cooperation amid a complex and volatile international environment.
The summit was held under the guidance of the Executive Committee of the Guangdong-Macao In-Depth Cooperation Zone in Hengqin and co-hosted by IQVIA, CICC Capital and the China-Portugal Economic and Trade Center. Leveraging the geographic and institutional advantages of the "Macao + Hengqin" model, the summit is dedicated to connecting Chinese innovative drug and medical device companies with global capital and industry resources, serving as a platform for international exchange and industrial matchmaking. Its goal is to deliver a batch of practical cooperation outcomes and enable more of these achievements to find precise landing and growth opportunities in Hengqin.
Aaron Gu's Profile
Aaron Gu specializes in corporate, regulatory compliance, and transactional services for life sciences, biopharmaceutical, medical and healthcare industries, including biosecurity and human genetic resource issues, clinical trial matters, product marketing authorizations, GxP compliance, Spin off-NewCo transactions, drug licensing and collaboration, as well as regulatory issues involved in venture capital and private equity investments, mergers and acquisitions, and foreign and outbound investments in the life sciences industries. Specifically, Aaron. Gu's services cover a full range of products including drugs, medical devices, IVDs, cosmetics, general foods, special foods, animal drugs, animal foods, etc. Furthermore, Aaron Gu has been interviewed by 36Kr, Blue View, Caixin, China Business Network, Dutch Financial Daily, Economic Observer, Faxian Magazine, Financial Times, Healthcare Executive, International Pharmaceutical News for China, Jiemian, Southern Weekly, Thomson Reuters and other media (in alphabetical order).
